个人简介

    潘超云，中山大学中山医学院教授，博士生导师，课题组负责人，中山大学逸仙优秀学者。2016年毕业于南京大学，获得博士学位；2016年-2020年在美国埃默里大学（Emory Univ.）从事博士后研究；2020年获得中山大学“百人计划”引进，任中山医学院生物化学与分子生物系副教授，2025年晋升教授。主持国家自然科学基金优秀青年项目、面上项目等，并担任广东省抗癌协会代谢专业委员会常务委员、广东省生物化学与分子生物学青年委员会副主任委员、BMC Biology 以及Scientific Reports 杂志副主编等。

    课题组以癌症为主要研究内容，聚焦人体代谢与细胞代谢在肿瘤发生、转移与治疗抵抗中的作用机制与相关临床转化研究。相关研究成果发表在Cell Metabolism, Journal of Clinical Investigation, Nat Communications, Molecular Cell, PNAS, Clinical Cancer Research, Advanced Science, Oncogene等杂志，并参与编写生物化学学科国家级规划教材4部。

学术成果

代表性学术论著

1.Zheng C, Niu G, Tan H, Huang X, Lu J, Mai Q, Yu T, Zhang C, Chen S, Wei M, Pan W, Guo Y, Wang J, Xu M, Yao S, Liu J, Li J, Pan C. A noncanonical role of SAT1 enables anchorage independence and peritoneal metastasis in ovarian cancer. Nat Commun. 2025;16(1):3174. Epub 2025/04/04. doi: 10.1038/s41467-025-58525-8. PubMed PMID: 40180916; PMCID: PMC11968987.

2.Zheng C, Tan H, Niu G, Huang X, Lu J, Chen S, Li H, Zhu J, Zhou Z, Xu M, Pan C, Liu J, Li J. ACAT1-Mediated ME2 Acetylation Drives Chemoresistance in Ovarian Cancer by Linking Glutaminolysis to Lactate Production. Adv Sci (Weinh). 2025:e2416467. Epub 2025/02/14. doi: 10.1002/advs.202416467. PubMed PMID: 39951294.

3.Li J, Zheng C, Mai Q, Huang X, Pan W, Lu J, Chen Z, Zhang S, Zhang C, Huang H, Chen Y, Guo H, Wu Z, Deng C, Jiang Y, Li B, Liu J, Yao S, Pan C. Tyrosine catabolism enhances genotoxic chemotherapy by suppressing translesion DNA synthesis in epithelial ovarian cancer. Cell Metab. 2023;35(11):2044-59 e8. Epub 2023/10/28. doi: 10.1016/j.cmet.2023.10.002. PubMed PMID: 37890478.

4.Li J, Lu J, Xu M, Yang S, Yu T, Zheng C, Huang X, Pan Y, Chen Y, Long J, Zhang C, Huang H, Dai Q, Li B, Wang W, Yao S, Pan C. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models. J Clin Invest. 2023;133(2). Epub 2022/11/16. doi: 10.1172/JCI161544. PubMed PMID: 36378528; PMCID: PMC9843051.

5.Boese AC, Kang J, Hwang JS, Kim J, Eun K, Malin CM, Magliocca KR, Pan C, Jin L, Kang S. Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis. Proc Natl Acad Sci U S A. 2023;120(23):e2217332120. Epub 2023/05/30. doi: 10.1073/pnas.2217332120. PubMed PMID: 37253003; PMCID: PMC10266061.

6.Liu Z, You Y, Chen Q, Li G, Pan W, Yang Q, Dong J, Wu Y, Bei JX, Pan C, Li F, Li B. Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis. Mol Ther. 2022;30(2):606-20. Epub 2021/10/04. doi: 10.1016/j.ymthe.2021.07.015. PubMed PMID: 34601133; PMCID: PMC8821954.

7.Li J, Zheng C, Wang M, Umano AD, Dai Q, Zhang C, Huang H, Yang Q, Yang X, Lu J, Pan W, Li B, Yao S, Pan C. ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer. Oncogene. 2022;41(8):1114-28. Epub 2022/01/19. doi: 10.1038/s41388-021-02149-x. PubMed PMID: 35039634.

8.Pan C, Li B, Simon MC. Moonlighting functions of metabolic enzymes and metabolites in cancer. Mol Cell. 2021;81(18):3760-74. Epub 2021/09/22. doi: 10.1016/j.molcel.2021.08.031. PubMed PMID: 34547237.

9.Pan C, Kang J, Hwang JS, Li J, Boese AC, Wang X, Yang L, Boggon TJ, Chen GZ, Saba NF, Shin DM, Magliocca KR, Jin L, Kang S. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. Nat Commun. 2021;12(1):4960. Epub 2021/08/18. doi: 10.1038/s41467-021-24845-8. PubMed PMID: 34400618; PMCID: PMC8368102 platinum-based chemotherapy" technology. The other authors declare no competing interests.

10.Li J, Pan C, Boese AC, Kang J, Umano AD, Magliocca KR, Yang W, Zhang Y, Lonial S, Jin L, Kang S. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling. Clin Cancer Res. 2020;26(14):3843-55. Epub 2020/04/29. doi: 10.1158/1078-0432.CCR-19-3790. PubMed PMID: 32341033; PMCID: PMC7367757.

11.Pan C, Jin L, Wang X, Li Y, Chun J, Boese AC, Li D, Kang HB, Zhang G, Zhou L, Chen GZ, Saba NF, Shin DM, Magliocca KR, Owonikoko TK, Mao H, Lonial S, Kang S. Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. J Clin Invest. 2019;129(6):2431-45. Epub 2019/05/14. doi: 10.1172/JCI124550. PubMed PMID: 31081803; PMCID: PMC6546469.

12.Pan C, Chun J, Li D, Boese AC, Li J, Kang J, Umano A, Jiang Y, Song L, Magliocca KR, Chen ZG, Saba NF, Shin DM, Owonikoko TK, Lonial S, Jin L, Kang S. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. J Clin Invest. 2019;129(10):4110-23. Epub 2019/08/27. doi: 10.1172/JCI125963. PubMed PMID: 31449053; PMCID: PMC6763259.